[Pathobiology and its clinical relevance in diffuse large B-cell lymphoma]

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Context:

• Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous hematologic malignancy with varied clinical and biological features.
• While rituximab combination chemotherapy improved outcomes, approximately 40% of patients experience recurrence with poor prognosis.
• Recent advancements include polatuzumab vedotin and CAR T-cell therapies, offering new hope but requiring patient stratification.

Purpose:

• To emphasize the critical need for further evaluation of DLBCL molecular pathogenesis.
• To highlight the role of genetic analysis in uncovering novel abnormalities and gene expression patterns.
• To establish a foundation for personalized medicine in DLBCL through molecular subtyping.

Summary:

• DLBCL heterogeneity necessitates ongoing research into its molecular underpinnings.
• Despite therapeutic progress, a significant patient subset faces recurrence, underscoring the need for refined treatment strategies.
• Genetic discoveries are paving the way for molecular classification and personalized therapeutic approaches.

Impact:

• Elucidating DLBCL molecular pathology will enable precise patient stratification for novel therapies.
• Advancements in genetic analysis are crucial for identifying biomarkers predictive of treatment response.
• Molecular subtyping of DLBCL is essential for the future development of personalized medicine and improved patient outcomes.